Barriers to Prevention, Eradication of HIV Remain Despite Numerous Advances
Since the first clinical observation of HIV/AIDS in 1981, some 35.4 million people have died from AIDS-related illnesses.
MPR YIR HIV 2018
Temixys Approved for the Treatment of HIV-1 Infection
Temixys combines lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), which are 2 nucleoside reverse transcriptase inhibitors.
USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients
Screening recommended for those ages 15 to 65 years, including pregnant women
HIV Transmission Risk Small With Antiretroviral Compliance
The researchers found that based on 1 review, HIV transmission risk for condom use without antiretroviral therapy was estimated at 1.14 transmissions/100 person-years (95% confidence interval, 0.56 to 2.04).
Labeling for Two HIV Drugs Updated With Safety, PK Data for Pregnant Patients
The “8.1 Pregnancy” and “12.3 Pharmacokinetics” sections have been updated with data showing no increase in the risk of overall major birth defects with 1st trimester exposure for rilpivirine.
High-Coverage Rollout of PrEP Tied to Drop in HIV Diagnoses
Pre-exposure prophylaxis implementation linked to rapid decline in HIV diagnoses among MSM
HIV PrEP Use Substantially Increased Between 2014 to 2016
“Barriers to the provision of PrEP for persons in populations with the highest rates of annual HIV diagnoses, such as black and Hispanic men and women, need to be better understood to help guide the development of interventions to increase access to and utilization of PrEP,” write the authors.
FDA Approves Two New Oral Treatments for HIV-1 Infection
Delstrigo is approved as a complete regimen whereas Pifeltro is to be administered in combination with other antiretrovirals.
Labeling for Several HIV Meds Updated to Include Interaction Data With DOACs
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
Protease Inhibitors May Worsen Outcomes in Patients With HIV + Heart Failure
The researchers found that patients who were receiving a PI had higher rates of hyperlipidemia, diabetes mellitus, and coronary artery disease.
